Hemophilia A – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Hemophilia A is an x-linked genetic disorder characterized by factor VIII deficiency. The liver is the predominant source of factor VIII, secreted and circulated in the bloodstream in an inactive form in a complex with von Willebrand factor. Several other tissues produce factor VIII, including the endothelium. Factor IX is produced entirely by the liver. Chronic hemarthroses are one of the most common long-term complications of hemophilia. Intra-articular bleeding may resolve on its own or with treatment in an acute case. However, many patients will experience recurrent bleeding and develop single or multiple target joints that are often painful and restrict their daily activity. Common sites are the knee, elbow, and ankle. Over time, chronic synovitis and chronic hemarthroses can result in degenerative joint disease, osteoarthritis, and osteophyte formation.
·
In the United States, most people with
hemophilia are diagnosed very young; Hemophilia A affects 1 in 5,000 male
births.
·
The prevalence varies among different parts of
the world, with a range of 5.4 - 14.5 cases per 100,000 males. In the United
States, the prevalence of hemophilia A is estimated to be 20.6 cases per
100,000 males.
Thelansis’s “Hemophilia A Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Hemophilia
A treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Hemophilia A across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Hemophilia A Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment